Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	monoatomic ion transport	PTPN3 ADRA2A ATP8A1 CLCN4 CLCN5 CATSPER2 HTR7 SLC15A2 WFS1 MTOR PIK3CG SLC5A6 CFTR KCNK2 CDH23 TRPV6 TRIM27 ATP2A1 UTRN CACNA2D3	5.57e-07	1374	85	20	GO:0006811
GeneOntologyBiologicalProcess	monoatomic ion transmembrane transport	PTPN3 ADRA2A ATP8A1 CLCN4 CLCN5 CATSPER2 SLC15A2 MTOR PIK3CG SLC5A6 CFTR KCNK2 TRPV6 ATP2A1 UTRN CACNA2D3	1.10e-05	1115	85	16	GO:0034220
GeneOntologyBiologicalProcess	inorganic ion transmembrane transport	PTPN3 ADRA2A CLCN4 CLCN5 CATSPER2 SLC15A2 MTOR PIK3CG SLC5A6 CFTR KCNK2 TRPV6 ATP2A1 UTRN CACNA2D3	1.57e-05	1017	85	15	GO:0098660
GeneOntologyBiologicalProcess	monoatomic cation transport	PTPN3 ADRA2A ATP8A1 CATSPER2 SLC15A2 WFS1 PIK3CG SLC5A6 CFTR KCNK2 CDH23 TRPV6 TRIM27 ATP2A1 UTRN CACNA2D3	1.75e-05	1157	85	16	GO:0006812
GeneOntologyBiologicalProcess	iodide transmembrane transport	MTOR SLC5A6	5.02e-05	3	85	2	GO:1904200
GeneOntologyBiologicalProcess	metal ion transport	PTPN3 ADRA2A CATSPER2 WFS1 PIK3CG SLC5A6 CFTR KCNK2 CDH23 TRPV6 TRIM27 ATP2A1 UTRN CACNA2D3	5.51e-05	1000	85	14	GO:0030001
GeneOntologyBiologicalProcess	regulation of inorganic anion transmembrane transport	MTOR CFTR	1.00e-04	4	85	2	GO:1903795
GeneOntologyBiologicalProcess	monoatomic cation transmembrane transport	PTPN3 ADRA2A ATP8A1 CATSPER2 SLC15A2 PIK3CG SLC5A6 CFTR KCNK2 TRPV6 ATP2A1 UTRN CACNA2D3	1.21e-04	942	85	13	GO:0098655
GeneOntologyBiologicalProcess	regulation of monoatomic ion transport	PTPN3 ADRA2A HTR7 WFS1 MTOR PIK3CG CFTR TRIM27 ATP2A1 UTRN	1.29e-04	577	85	10	GO:0043269
GeneOntologyBiologicalProcess	inorganic anion transmembrane transport	CLCN4 CLCN5 MTOR SLC5A6 CFTR	2.32e-04	134	85	5	GO:0098661
GeneOntologyBiologicalProcess	calcium ion transport	ADRA2A CATSPER2 WFS1 PIK3CG CDH23 TRPV6 TRIM27 ATP2A1 CACNA2D3	2.47e-04	509	85	9	GO:0006816
GeneOntologyBiologicalProcess	peptidyl-tryptophan modification	DPY19L2 DPY19L2P2	2.49e-04	6	85	2	GO:0018211
GeneOntologyBiologicalProcess	protein C-linked glycosylation via tryptophan	DPY19L2 DPY19L2P2	2.49e-04	6	85	2	GO:0018317
GeneOntologyBiologicalProcess	protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan	DPY19L2 DPY19L2P2	2.49e-04	6	85	2	GO:0018406
GeneOntologyBiologicalProcess	protein C-linked glycosylation	DPY19L2 DPY19L2P2	2.49e-04	6	85	2	GO:0018103
Domain	ARM-type_fold	FOCAD RALGAPA1 RIF1 MTOR PIK3CG PI4KA MROH2B APC2 RTTN CUL9 RALGAPA2 VIRMA SYMPK	3.62e-09	339	84	13	IPR016024
Domain	Actinin_actin-bd_CS	SPTBN1 SYNE2 MACF1 UTRN	3.16e-06	23	84	4	IPR001589
Domain	Spectrin	SPTBN1 SYNE2 MACF1 UTRN	3.16e-06	23	84	4	PF00435
Domain	ACTININ_2	SPTBN1 SYNE2 MACF1 UTRN	3.16e-06	23	84	4	PS00020
Domain	ACTININ_1	SPTBN1 SYNE2 MACF1 UTRN	3.16e-06	23	84	4	PS00019
Domain	-	RIF1 MTOR MROH2B APC2 RTTN CUL9 MED12 SYMPK	7.05e-06	222	84	8	1.25.10.10
Domain	Spectrin_repeat	SPTBN1 SYNE2 MACF1 UTRN	8.30e-06	29	84	4	IPR002017
Domain	Spectrin/alpha-actinin	SPTBN1 SYNE2 MACF1 UTRN	1.24e-05	32	84	4	IPR018159
Domain	SPEC	SPTBN1 SYNE2 MACF1 UTRN	1.24e-05	32	84	4	SM00150
Domain	ARM-like	RIF1 MTOR MROH2B APC2 RTTN CUL9 MED12 SYMPK	2.90e-05	270	84	8	IPR011989
Domain	PI3/4_kinase_CS	MTOR PIK3CG PI4KA	3.84e-05	15	84	3	IPR018936
Domain	-	MTOR PIK3CG PI4KA	4.71e-05	16	84	3	1.10.1070.11
Domain	PI3Kc	MTOR PIK3CG PI4KA	4.71e-05	16	84	3	SM00146
Domain	PI3/4_kinase_cat_dom	MTOR PIK3CG PI4KA	6.82e-05	18	84	3	IPR000403
Domain	PI3_PI4_kinase	MTOR PIK3CG PI4KA	6.82e-05	18	84	3	PF00454
Domain	PI3_4_KINASE_3	MTOR PIK3CG PI4KA	6.82e-05	18	84	3	PS50290
Domain	PI3_4_KINASE_1	MTOR PIK3CG PI4KA	6.82e-05	18	84	3	PS00915
Domain	PI3_4_KINASE_2	MTOR PIK3CG PI4KA	6.82e-05	18	84	3	PS00916
Domain	CH	SPTBN1 SYNE2 MACF1 UTRN	2.09e-04	65	84	4	SM00033
Domain	CH	SPTBN1 SYNE2 MACF1 UTRN	2.78e-04	70	84	4	PF00307
Domain	-	SPTBN1 SYNE2 MACF1 UTRN	2.94e-04	71	84	4	1.10.418.10
Domain	Melcrt_ACTH_rcpt	HTR7 MC3R	2.96e-04	6	84	2	IPR001671
Domain	CH	SPTBN1 SYNE2 MACF1 UTRN	3.27e-04	73	84	4	PS50021
Domain	CH-domain	SPTBN1 SYNE2 MACF1 UTRN	3.63e-04	75	84	4	IPR001715
Domain	-	ATP8B3 ATP8A1 ATP2A1	3.96e-04	32	84	3	3.40.1110.10
Domain	-	ATP8B3 ATP8A1 ATP2A1	3.96e-04	32	84	3	2.70.150.10
Domain	HAD-like_dom	ATP8B3 ATP8A1 ATP2A1 NT5DC3	4.43e-04	79	84	4	IPR023214
Domain	ATPase_P-typ_cyto_domN	ATP8B3 ATP8A1 ATP2A1	5.18e-04	35	84	3	IPR023299
Domain	P_typ_ATPase	ATP8B3 ATP8A1 ATP2A1	5.63e-04	36	84	3	IPR001757
Domain	ATPase_P-typ_P_site	ATP8B3 ATP8A1 ATP2A1	5.63e-04	36	84	3	IPR018303
Domain	ATPASE_E1_E2	ATP8B3 ATP8A1 ATP2A1	5.63e-04	36	84	3	PS00154
Domain	ATPase_P-typ_transduc_dom_A	ATP8B3 ATP8A1 ATP2A1	6.11e-04	37	84	3	IPR008250
Domain	E1-E2_ATPase	ATP8B3 ATP8A1 ATP2A1	6.11e-04	37	84	3	PF00122
Domain	Cl-channel_core	CLCN4 CLCN5	7.05e-04	9	84	2	IPR014743
Domain	Plexin_cytopl	PLXNB1 PLXNB3	7.05e-04	9	84	2	PF08337
Domain	PI3Ka	PIK3CG PI4KA	7.05e-04	9	84	2	PF00613
Domain	Plexin_cytoplasmic_RasGAP_dom	PLXNB1 PLXNB3	7.05e-04	9	84	2	IPR013548
Domain	Plexin	PLXNB1 PLXNB3	7.05e-04	9	84	2	IPR031148
Domain	-	CLCN4 CLCN5	7.05e-04	9	84	2	1.10.3080.10
Domain	Voltage_CLC	CLCN4 CLCN5	7.05e-04	9	84	2	PF00654
Domain	Cl-channel_volt-gated	CLCN4 CLCN5	7.05e-04	9	84	2	IPR001807
Domain	-	PIK3CG PI4KA	7.05e-04	9	84	2	1.25.40.70
Domain	PI3Ka	PIK3CG PI4KA	7.05e-04	9	84	2	SM00145
Domain	Hydrolase_3	ATP8B3 ATP2A1	8.79e-04	10	84	2	PF08282
Domain	Rap_GAP	RALGAPA1 RALGAPA2	8.79e-04	10	84	2	PF02145
Domain	PIK_HELICAL	PIK3CG PI4KA	8.79e-04	10	84	2	PS51545
Domain	PI_Kinase	PIK3CG PI4KA	8.79e-04	10	84	2	IPR015433
Domain	PInositide-3_kin_accessory_dom	PIK3CG PI4KA	8.79e-04	10	84	2	IPR001263
Domain	Rap_GAP_dom	RALGAPA1 RALGAPA2	1.07e-03	11	84	2	IPR000331
Domain	RAPGAP	RALGAPA1 RALGAPA2	1.07e-03	11	84	2	PS50085
Domain	HTH_Tnp_Tc5	DCHS2 TIGD1	1.51e-03	13	84	2	PF03221
Domain	7TM_GPCR_Srsx	NPFFR2 ADRA2A HTR1E MC3R	1.64e-03	112	84	4	SM01381
Domain	P_typ_ATPase_c	ATP8B3 ATP8A1	1.76e-03	14	84	2	IPR032630
Domain	P-type_ATPase_N	ATP8B3 ATP8A1	1.76e-03	14	84	2	IPR032631
Domain	P-type_ATPase_IV	ATP8B3 ATP8A1	1.76e-03	14	84	2	IPR006539
Domain	PhoLip_ATPase_C	ATP8B3 ATP8A1	1.76e-03	14	84	2	PF16212
Domain	PhoLip_ATPase_N	ATP8B3 ATP8A1	1.76e-03	14	84	2	PF16209
Domain	CBS	CLCN4 CLCN5	2.30e-03	16	84	2	SM00116
Domain	-	ATP8B3 ATP8A1 NT5DC3	3.00e-03	64	84	3	3.40.50.1000
Domain	CBS_dom	CLCN4 CLCN5	3.60e-03	20	84	2	IPR000644
Domain	CBS	CLCN4 CLCN5	3.60e-03	20	84	2	PF00571
Domain	CBS	CLCN4 CLCN5	3.60e-03	20	84	2	PS51371
Pubmed	Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists.	ADRA2A PTPRD PIK3CG TRIM27	6.12e-08	15	92	4	20526338
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	FOCAD DCHS2 PTPRD FCGR1A CORO2A SPTBN1 TMEM59 APC2 CUL9 MACF1 DCN UTRN PREPL ADAM22 PLXNB3 TXNDC11	2.46e-07	1285	92	16	35914814
Pubmed	Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.	MTOR PIK3CG	6.92e-06	2	92	2	20166697
Pubmed	Identification and functional characterization of a voltage-gated chloride channel and its novel splice variant in taste bud cells.	CLCN4 CLCN5	6.92e-06	2	92	2	16129671
Pubmed	CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.	PIK3CG CD160	6.92e-06	2	92	2	20164468
Pubmed	Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support.	MTOR PIK3CG	6.92e-06	2	92	2	15496972
Pubmed	Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells.	MTOR PIK3CG	6.92e-06	2	92	2	20157617
Pubmed	ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes.	LPL C3	6.92e-06	2	92	2	14703506
Pubmed	Genetics of hearing loss: Allelism and modifier genes produce a phenotypic continuum.	WFS1 CDH23	6.92e-06	2	92	2	16550584
Pubmed	Dpy19l2-deficient globozoospermic sperm display altered genome packaging and DNA damage that compromises the initiation of embryo development.	DPY19L2 DPY19L2P2	6.92e-06	2	92	2	25354700
Pubmed	Subcellular localization of phospholipase Cζ in human sperm and its absence in DPY19L2-deficient sperm are consistent with its role in oocyte activation.	DPY19L2 DPY19L2P2	6.92e-06	2	92	2	25354701
Pubmed	Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5.	CLCN4 CLCN5	6.92e-06	2	92	2	16034421
Pubmed	SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.	MTOR SPAG5	6.92e-06	2	92	2	24853425
Pubmed	Absence of Dpy19l2, a new inner nuclear membrane protein, causes globozoospermia in mice by preventing the anchoring of the acrosome to the nucleus.	DPY19L2 DPY19L2P2	6.92e-06	2	92	2	22764053
Pubmed	A novel aminophospholipid transporter exclusively expressed in spermatozoa is required for membrane lipid asymmetry and normal fertilization.	ATP8B3 ATP8A1	6.92e-06	2	92	2	14975727
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	RIF1 MTOR SPTBN1 SYNE2 CUL9 MACF1 UTRN VIRMA MED12 SYMPK	9.20e-06	653	92	10	22586326
Pubmed	Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo.	MTOR PIK3CG PI4KA	1.19e-05	17	92	3	25327288
Pubmed	The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.	RALGAPA1 PTPN3 RHPN2 MTOR DNAJC16 PI4KA CFTR RALGAPA2 PLXNB1	2.05e-05	569	92	9	30639242
Pubmed	The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.	MTOR PIK3CG	2.07e-05	3	92	2	19897009
Pubmed	Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.	MTOR PIK3CG	2.07e-05	3	92	2	18395956
Pubmed	Evidence of evolutionary up-regulation of the single active X chromosome in mammals based on Clc4 expression levels in Mus spretus and Mus musculus.	CLCN4 CLCN5	2.07e-05	3	92	2	9256467
Pubmed	Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.	MTOR PIK3CG	2.07e-05	3	92	2	21707707
Pubmed	Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.	MTOR PIK3CG	2.07e-05	3	92	2	19078992
Pubmed	Duplication and relocation of the functional DPY19L2 gene within low copy repeats.	DPY19L2 DPY19L2P2	2.07e-05	3	92	2	16526957
Pubmed	Chromosomal locations and gonadal dependence of genes that mediate resistance to ectromelia (mousepox) virus-induced mortality.	LPL C3	2.07e-05	3	92	2	2002550
Pubmed	Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.	MTOR PIK3CG	2.07e-05	3	92	2	19615795
Pubmed	Dynamics of Sun5 localization during spermatogenesis in wild type and Dpy19l2 knock-out mice indicates that Sun5 is not involved in acrosome attachment to the nuclear envelope.	DPY19L2 DPY19L2P2	2.07e-05	3	92	2	25775128
Pubmed	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.	MTOR PIK3CG	2.07e-05	3	92	2	20530239
Pubmed	Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases.	RALGAPA1 RALGAPA2	2.07e-05	3	92	2	19520869
Pubmed	SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.	MTOR SPAG5	2.07e-05	3	92	2	29662193
Pubmed	Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.	MTOR PIK3CG	2.07e-05	3	92	2	24008870
Pubmed	Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.	MTOR PIK3CG	2.07e-05	3	92	2	18652687
Pubmed	Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors.	ADRA2A HTR7	2.07e-05	3	92	2	15026130
Pubmed	The essential role of complement in antibody-mediated resistance to Salmonella.	FCGR1A C3	2.07e-05	3	92	2	30179254
Pubmed	Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.	MTOR PIK3CG	2.07e-05	3	92	2	20030877
Pubmed	Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells.	MTOR PIK3CG	2.07e-05	3	92	2	15001544
Pubmed	Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling.	MTOR PIK3CG	2.07e-05	3	92	2	20488790
Pubmed	A common variant in DRD3 receptor is associated with autism spectrum disorder.	ADRA2A HTR1E ABCA13 PIK3CG MC3R	2.38e-05	128	92	5	19058789
Pubmed	A contravention of Ohno's law in mice.	CLCN4 CLCN5	4.14e-05	4	92	2	7670497
Pubmed	Different chromosomal localization of the Clcn4 gene in Mus spretus and C57BL/6J mice.	CLCN4 CLCN5	4.14e-05	4	92	2	7670496
Pubmed	A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.	MTOR PIK3CG	4.14e-05	4	92	2	23107319
Pubmed	Role of ClC-5 in renal endocytosis is unique among ClC exchangers and does not require PY-motif-dependent ubiquitylation.	CLCN4 CLCN5	4.14e-05	4	92	2	20351103
Pubmed	C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcgamma receptors.	FCGR1A C3	4.14e-05	4	92	2	17182593
Pubmed	Plexin-B family members demonstrate non-redundant expression patterns in the developing mouse nervous system: an anatomical basis for morphogenetic effects of Sema4D during development.	PLXNB1 PLXNB3	4.14e-05	4	92	2	15147296
Pubmed	Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.	MTOR PIK3CG	4.14e-05	4	92	2	17724079
Pubmed	Mutational analysis of CLC-5, cofilin and CLC-4 in patients with Dent's disease.	CLCN4 CLCN5	4.14e-05	4	92	2	19546591
Pubmed	LPL/AQP7/GPD2 promotes glycerol metabolism under hypoxia and prevents cardiac dysfunction during ischemia.	LPL AQP7	4.14e-05	4	92	2	34807469
Pubmed	Adipose tissue gene expression of factors related to lipid processing in obesity.	LPL C3	4.14e-05	4	92	2	21966368
Pubmed	Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells.	MTOR SPAG5	6.89e-05	5	92	2	23953116
Pubmed	Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF.	PLXNB1 PLXNB3	6.89e-05	5	92	2	12183458
Pubmed	Promising molecular targets in ovarian cancer.	MTOR PIK3CG	6.89e-05	5	92	2	19553815
Pubmed	FAM209 associates with DPY19L2, and is required for sperm acrosome biogenesis and fertility in mice.	DPY19L2 DPY19L2P2	6.89e-05	5	92	2	34471926
Pubmed	Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin.	MTOR PIK3CG	6.89e-05	5	92	2	17942603
Pubmed	Caveolin-1 increases basal and TGF-beta1-induced expression of type I procollagen through PI-3 kinase/Akt/mTOR pathway in human dermal fibroblasts.	MTOR PIK3CG	6.89e-05	5	92	2	18434090
Pubmed	IgG is elevated in obese white adipose tissue but does not induce glucose intolerance via Fcγ-receptor or complement.	FCGR1A C3	6.89e-05	5	92	2	28852207
Pubmed	Plexin-B3 is a functional receptor for semaphorin 5A.	PLXNB1 PLXNB3	6.89e-05	5	92	2	15218527
Pubmed	Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.	FCGR1A C3	6.89e-05	5	92	2	17485663
Pubmed	Interplay between scatter factor receptors and B plexins controls invasive growth.	PLXNB1 PLXNB3	6.89e-05	5	92	2	15184888
Pubmed	An essential role for ClC-4 in transferrin receptor function revealed in studies of fibroblasts derived from Clcn4-null mice.	CLCN4 CLCN5	6.89e-05	5	92	2	19339555
Pubmed	The Tumor Suppressor SASH1 Interacts With the Signal Adaptor CRKL to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.	SPTBN1 SYNE2 UTRN	6.91e-05	30	92	3	30480076
Pubmed	Optimized fragmentation schemes and data analysis strategies for proteome-wide cross-link identification.	RALGAPA1 PPP1R10 RIF1 MTOR PI4KA SPTBN1 MACF1 UTRN	9.29e-05	538	92	8	28524877
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	RALGAPA1 PTPN3 MTOR PI4KA SPTBN1 SYNE2 MACF1 UTRN VIRMA DOP1A	9.49e-05	861	92	10	36931259
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	RALGAPA1 ATP8A1 FCGR1A CORO2A WFS1 PI4KA SPTBN1 MACF1 NT5DC3 UTRN VIRMA ADAM22 CACNA2D3	9.96e-05	1431	92	13	37142655
Pubmed	HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP.	GIN1 MACF1 UTRN	1.01e-04	34	92	3	25925205
Pubmed	Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.	FCGR1A C3	1.03e-04	6	92	2	35108544
Pubmed	Expression of CLCN voltage-gated chloride channel genes in human blood vessels.	CLCN4 CLCN5	1.03e-04	6	92	2	10198195
Pubmed	Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo.	FCGR1A C3	1.03e-04	6	92	2	16513171
Pubmed	Quantitative trait loci associated with blood pressure of metabolic syndrome in the progeny of NZO/HILtJxC3H/HeJ intercrosses.	LPL KCNK2	1.03e-04	6	92	2	17641813
Pubmed	Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcγ receptors in a murine model.	FCGR1A C3	1.03e-04	6	92	2	22502635
Pubmed	Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.	FCGR1A C3	1.03e-04	6	92	2	28756234
Pubmed	Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling.	RALGAPA1 MTOR PI4KA SPTBN1 MACF1 ADAM22	1.05e-04	281	92	6	28706196
Pubmed	Sequential use of transcriptional profiling, expression quantitative trait mapping, and gene association implicates MMP20 in human kidney aging.	ADRA2A LPL C3 DCN	1.37e-04	98	92	4	19834535
Pubmed	SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway.	MTOR SPAG5	1.44e-04	7	92	2	31957155
Pubmed	Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.	FCGR1A C3	1.44e-04	7	92	2	18209093
Pubmed	The collagen derived dipeptide hydroxyprolyl-glycine promotes C2C12 myoblast differentiation and myotube hypertrophy.	SLC15A2 MTOR	1.44e-04	7	92	2	27553280
Pubmed	CDC50 proteins are critical components of the human class-1 P4-ATPase transport machinery.	ATP8B3 ATP8A1	1.44e-04	7	92	2	20961850
Pubmed	Ex vivo Quantitative Proteomic Analysis of Serotonin Transporter Interactome: Network Impact of the SERT Ala56 Coding Variant.	RALGAPA1 CORO2A WFS1 CFTR APC2 MACF1 ADAM22	1.49e-04	430	92	7	32581705
Pubmed	Molecular genetics of successful smoking cessation: convergent genome-wide association study results.	ATP8A1 PTPRD KCNK2 CACNA2D3	1.54e-04	101	92	4	18519826
Pubmed	Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?	ADRA2A HTR7 PIK3CG LPL MC3R	1.62e-04	192	92	5	20602615
Pubmed	F-box only protein 9 is an E3 ubiquitin ligase of PPARγ.	TIGD1 TRPV6 ADAM22	1.65e-04	40	92	3	27197753
Pubmed	The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1.	RALGAPA1 SYNE2 MACF1 UTRN VIRMA	1.83e-04	197	92	5	20811636
Pubmed	The expression of plexins during mouse embryogenesis.	PLXNB1 PLXNB3	1.92e-04	8	92	2	15661641
Pubmed	Divergent immunoglobulin g subclass activity through selective Fc receptor binding.	FCGR1A C3	1.92e-04	8	92	2	16322460
Pubmed	Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.	FCGR1A C3	1.92e-04	8	92	2	16453025
Pubmed	Association analyses of genetic polymorphisms of GSTM1, GSTT1, NQO1, NAT2, LPL, PRSS1, PSTI, and CFTR with chronic alcoholic pancreatitis in Japan.	LPL CFTR	1.92e-04	8	92	2	18986377
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	PTPRD MTOR PI4KA SPTBN1 SYNE2 APC2 MACF1 VIRMA PREPL ADAM22	2.35e-04	963	92	10	28671696
Pubmed	Changing expression of chloride channels during preimplantation mouse development.	CLCN4 CLCN5	2.46e-04	9	92	2	23115349
Pubmed	Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.	ADRA2A PIK3CG LPL MC3R	2.71e-04	117	92	4	18996102
Pubmed	HENA, heterogeneous network-based data set for Alzheimer's disease.	SPTBN1 MACF1 TRIM27 SPAG5	2.98e-04	120	92	4	31413325
Pubmed	Oscillatory flow-induced proliferation of osteoblast-like cells is mediated by alphavbeta3 and beta1 integrins through synergistic interactions of focal adhesion kinase and Shc with phosphatidylinositol 3-kinase and the Akt/mTOR/p70S6K pathway.	MTOR PIK3CG	3.07e-04	10	92	2	19889638
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	WFS1 DNAJC16 SLC5A6 LPL TMEM59 ADAM22 DSE PLXNB1 TXNDC11 SPAG5 SYMPK	3.32e-04	1201	92	11	35696571
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	LIG4 RHPN2 DNAJC16 LPL METTL16 INTS3 PLXNB1 SPAG5	3.35e-04	650	92	8	38777146
Pubmed	A candidate gene study of obstructive sleep apnea in European Americans and African Americans.	ADRA2A LPL MC3R	3.60e-04	52	92	3	20538960
Pubmed	Variants in LRRC7 lead to intellectual disability, autism, aggression and abnormal eating behaviors.	SPTBN1 MACF1	3.75e-04	11	92	2	39256359
Pubmed	Immunoglobulins drive terminal maturation of splenic dendritic cells.	FCGR1A C3	3.75e-04	11	92	2	23345431
Pubmed	53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polα-dependent fill-in.	LIG4 RIF1	3.75e-04	11	92	2	30022158
Pubmed	HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway.	MTOR PIK3CG	3.75e-04	11	92	2	25104021
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	DNAJC16 MACF1 TEX15 TRIM27 VIRMA	4.04e-04	234	92	5	36243803
Pubmed	Ubiquitin-Independent Disassembly by a p97 AAA-ATPase Complex Drives PP1 Holoenzyme Formation.	PPP1R10 RIF1 SPTBN1 TRIM27 VIRMA SPAG5	4.04e-04	361	92	6	30344098
Pubmed	Mouse screen reveals multiple new genes underlying mouse and human hearing loss.	PTPRD MTOR PIK3CG SLC5A6 SPTBN1 CDH23 DCN VIRMA PLXNB3 SYMPK MTFMT	4.40e-04	1242	92	11	30973865
GeneFamily	Plexins	PLXNB1 PLXNB3	4.51e-04	9	65	2	683
GeneFamily	Chloride voltage-gated channels	CLCN4 CLCN5	5.62e-04	10	65	2	302
GeneFamily	5-hydroxytryptamine receptors, G protein-coupled	HTR1E HTR7	9.68e-04	13	65	2	170
GeneFamily	ATPase phospholipid transporting	ATP8B3 ATP8A1	1.30e-03	15	65	2	1210
GeneFamily	Cadherin related	DCHS2 CDH23	1.67e-03	17	65	2	24
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	RALGAPA1 PPP1R10 RIF1 ATP8A1 PIK3CG MACF1 RALGAPA2 UTRN	2.03e-07	180	90	8	M8239
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / Treatment groups by lineage, cell group, cell type	ATP8A1 SLC15A2 SYNE2 C3 UTRN PLXNB1 CACNA2D3	1.82e-07	200	91	7	2dadf317a42a7e27cc1fac74f91b806c93a57108
ToppCell	LPS_only-Epithelial_alveolar-AT_1\|LPS_only / Treatment groups by lineage, cell group, cell type	ATP8A1 SLC15A2 SYNE2 C3 UTRN PLXNB1 CACNA2D3	1.82e-07	200	91	7	9a6ae40f3e17cd44ee5fd73260713b920aa2ea15
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NPFFR2 DCHS2 ADRA2A CFTR KCNK2 UTRN	1.23e-06	167	91	6	a6ff7a3d9b80839c0efa91658836812e868561fa
ToppCell	facs-Large_Intestine-Proximal-3m-Epithelial\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADRA2A PTPRD CORO2A LPL SYNE2 DCN	1.51e-06	173	91	6	e1378201b15ffb98e196ac39fe3ee4b4078953bd
ToppCell	facs-Large_Intestine-Proximal-3m\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADRA2A PTPRD CORO2A LPL SYNE2 DCN	1.51e-06	173	91	6	99532bb768ee35fed939a377acb5215d3f8904bd
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR SEC11C C3 CACNA2D3	1.84e-06	179	91	6	7db6b97a1c4c7a163d5da4351ba36ac1785d9d7b
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR SEC11C C3 CACNA2D3	1.90e-06	180	91	6	b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCell	Control-Epithelial_alveolar-AT_2-Differentiating_AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 HTR1E ATP8A1 CFTR C3 CACNA2D3	2.22e-06	185	91	6	0d2add28ac1f4fa6de7699be009bf8391badaf4c
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	RALGAPA1 PPP1R10 ATP8A1 SYNE2 MACF1 UTRN	2.44e-06	188	91	6	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)-Goblet_(subsegmental)_L.0.4.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ADRA2A SLC15A2 ABCA13 CFTR TMEM59 C3	3.01e-06	195	91	6	2a9a36df1dbc4eac77a8ddbe939ec8a8d6c41464
ToppCell	LPS_IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ATP8A1 SLC15A2 SYNE2 C3 UTRN PLXNB1	3.19e-06	197	91	6	b94645d57efe8d9e032bffb8c89af1f425c6421e
ToppCell	LPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_only / Treatment groups by lineage, cell group, cell type	PTPN3 ATP8A1 CFTR SYNE2 C3 PLXNB1	3.19e-06	197	91	6	1a1bee8da6e04b65935c40373eaee4d6c046d9a1
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SLC15A2 SYNE2 C3 UTRN PLXNB1 CACNA2D3	3.39e-06	199	91	6	1c70e7d6bd25980e1b92aa1cac3f3c95d9651b4b
ToppCell	Neuronal-Excitatory-eE(FEZF2_SLC17A7)\|Neuronal / cells hierarchy compared to all cells using T-Statistic	NPFFR2 DCHS2 ADRA2A CFTR KCNK2 UTRN	3.48e-06	200	91	6	501cd2b4e55444fc5fdd93ebbcfc0616442b110b
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SLC15A2 SYNE2 C3 UTRN PLXNB1 CACNA2D3	3.48e-06	200	91	6	ddfb1f006365bf16203ee49f20200f68220cc288
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ATP8A1 SLC15A2 SYNE2 UTRN PLXNB1 CACNA2D3	3.48e-06	200	91	6	8683445ad5b70748c4a1f12eb77d47623085147e
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)-Cplx3-Inhibitory_Neuron.Gad1Gad2.Cplx3-Egln3_(Cortical_subplate_interneuron)-\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	ABCA13 C3 CD160 TMPRSS11A	4.25e-06	53	91	4	5fa009c9f30c77de6cece40a47da46241f1de54c
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)-Cplx3-Inhibitory_Neuron.Gad1Gad2.Cplx3-Egln3_(Cortical_subplate_interneuron)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	ABCA13 C3 CD160 TMPRSS11A	4.25e-06	53	91	4	52a1f2a041e3ba2b11ed753f2f57b78e68b5cc0c
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATP8A1 C3 UTRN CACNA2D3 TMPRSS11A	7.10e-06	130	91	5	6434d9106ccb38786dad36fab80163dfc07b6eb7
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PTPN3 DPY19L2 TRPV6 NT5DC3 ADAM22	1.56e-05	153	91	5	79c4f4ccdc8249c8461075c73491bc3b2d13344a
ToppCell	facs-Marrow-T_cells-18m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC15A2 LPL AQP7 DSE PLXNB3	1.72e-05	156	91	5	5caefdc6cc86f2ac52abe8c8da821db14f476915
ToppCell	facs-Marrow-T_cells-18m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC15A2 LPL AQP7 DSE PLXNB3	1.72e-05	156	91	5	758f57dc10fc5cad200bf5b310c10ec9b1405f23
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PTPN3 DPY19L2 TRPV6 NT5DC3 ADAM22	1.88e-05	159	91	5	50d951cf27a571c0c5002003c16fbc370fa17eb1
ToppCell	10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	RALGAPA1 SPTBN1 SYNE2 MACF1 UTRN	2.06e-05	162	91	5	b4535bcb3f469bc139e73f1122f4070013e5a1de
ToppCell	E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_prolif\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PTPN3 CORO2A PIK3CG LPL C3	2.52e-05	169	91	5	305cedbd97059029d7d2a248a8a4b6cfe281aa54
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_KRT17\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NPFFR2 DCHS2 ADRA2A CFTR KCNK2	2.60e-05	170	91	5	84d49a1f2989d98bd0acf9ec2d59f1042fc0f55b
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NPFFR2 RHPN2 ABCA13 C3 CACNA2D3	2.75e-05	172	91	5	0c2d0bb767e5ce089b42ad49e8b303a103de2d5c
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_KRT17\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NPFFR2 DCHS2 ADRA2A CFTR UTRN	2.75e-05	172	91	5	adc09c4d1b63fe84150516beb692db1e7f7ac980
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NPFFR2 DCHS2 ADRA2A CFTR KCNK2	2.75e-05	172	91	5	cecfe5cf20f317ea01b4604789e07a14481c4cd6
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NPFFR2 RHPN2 ABCA13 C3 CACNA2D3	2.75e-05	172	91	5	eeed177a03c116e9815a8e086d24efc9643b16a4
ToppCell	3'-Child09-12-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MROH2B KCNK2 C3 TSKS DCN	2.82e-05	173	91	5	11e95a60b5f6f07f27154a23203bac431e7528c6
ToppCell	PND01-03-samps-Epithelial-Alveolar_epithelial-AT2\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	ATP8A1 SLC15A2 CFTR TRPV6 TEX15	3.07e-05	176	91	5	ac76f2cd6c63f30b38b89b58bad2baa4dde8ce3a
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NPFFR2 DCHS2 ADRA2A CFTR UTRN	3.07e-05	176	91	5	ed421d8525108d2f585265d2cf777f07b29f44f0
ToppCell	LPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 SYNE2 C3 CACNA2D3	3.32e-05	179	91	5	fd2cbee532e7b44113410dca82aec7db1a7fb69f
ToppCell	LPS_only-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR SEC11C CACNA2D3	3.50e-05	181	91	5	0513b9e6673ff7bf8e72ba123ca3794b65d10170
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8\|Liver / Manually curated celltypes from each tissue	RALGAPA1 PPP1R10 ATP8A1 SYNE2 MACF1	3.50e-05	181	91	5	f2315414e714ac86211546a935660c4be6e85f1b
ToppCell	droplet-Marrow-nan-3m-Hematologic-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PPP1R10 SPTBN1 MACF1 UTRN CD160	3.60e-05	182	91	5	e78ba2c5cae480c16a596ce7c3bf2d480becacf4
ToppCell	droplet-Marrow-nan-3m-Hematologic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PPP1R10 SPTBN1 MACF1 UTRN CD160	3.60e-05	182	91	5	1710eab3037a87609d21838be2d2d29c3bc36651
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATP8A1 SYNE2 C3 UTRN CACNA2D3	3.79e-05	184	91	5	42ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 SEC11C C3 CACNA2D3	3.79e-05	184	91	5	d0c212a8fbaad24597a84018442b25c61c17ea58
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR C3 CACNA2D3	3.79e-05	184	91	5	ab2f06906fc7a9931dfa0864ef506832b07fb93e
ToppCell	droplet-Lung-nan-21m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC15A2 CFTR TRPV6 SERPINA10 PLXNB1	3.89e-05	185	91	5	6938ac3cab536cf8a474eba441ce6dcdfcc43b53
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ATP8A1 SLC15A2 CFTR TRPV6 TEX15	3.89e-05	185	91	5	2adb32096aa3473f8d417e5ce9e65264beca9b52
ToppCell	droplet-Lung-nan-21m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC15A2 CFTR TRPV6 SERPINA10 PLXNB1	3.89e-05	185	91	5	0e7351cd6d6e6e8c29573042e168da50ee496cfc
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR SEC11C C3	3.89e-05	185	91	5	fefaf227d89f680d6f3e91c4a94e26ab4d0dc6c3
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR SEC11C C3	3.89e-05	185	91	5	929b68b05b7686341329ac756d7df172cb4b810b
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATP8A1 SYNE2 C3 UTRN CACNA2D3	4.09e-05	187	91	5	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	droplet-Marrow-nan-3m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA13 SPTBN1 SYNE2 C3 MBNL3	4.09e-05	187	91	5	14c239af77116d28d511dea754b6150d20488080
ToppCell	LPS-IL1RA-Epithelial_alveolar\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 SEC11C C3 CACNA2D3	4.20e-05	188	91	5	6164d467b612767ceba15de34176bcc8e8c36ab8
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN3 ATP8A1 CFTR C3 CACNA2D3	4.20e-05	188	91	5	4bdf8d49af0e9da349b16e3f012e1b0eec04cc4f
ToppCell	facs-Lung-EPCAM-24m-Mesenchymal\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD KCNK2 MACF1 C3 DCN	4.31e-05	189	91	5	324c81285c51f4f8bb1aef428b18fe2c549c2c11
ToppCell	T_cells-GZMK+_CD8+_T_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	ATP8A1 SYNE2 MACF1 CD160 TRAV17	4.31e-05	189	91	5	e2ca075aedf7c370ab4ede6272254ffd06cbcdec
ToppCell	PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ATP8A1 SLC15A2 CFTR C3 TEX15	4.41e-05	190	91	5	8ff8c586237cf15f930416710bcff45205fe6f70
ToppCell	PND14-Epithelial-Epithelial_Alveolar\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ATP8A1 SLC15A2 CFTR C3 TEX15	4.53e-05	191	91	5	5f8b3b2d38b37027901db9a1cccdbd1ff70f29de
ToppCell	PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ATP8A1 SLC15A2 CFTR C3 TEX15	4.53e-05	191	91	5	2f71f1fb6b5872d84860840b22e789a87ab14eec
ToppCell	COVID-19-kidney-Mito-rich_Distal\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PTPN3 CLCN5 SYNE2 UGT2B7 CACNA2D3	4.53e-05	191	91	5	0965f621ebcd92ccdeb21cc27022180ce3cfe910
ToppCell	PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ATP8A1 SLC15A2 CFTR C3 TEX15	4.53e-05	191	91	5	4ab3056f9af2a6caed39f32288562f480811cd7b
ToppCell	background-NK_cells\|background / Sample and Cell Type and Tumor Cluster (all cells)	ATP8A1 PTPRD PIK3CG UTRN CD160	4.76e-05	193	91	5	f8d6eff1e04926f85d265ec39fe66897fe29574d
ToppCell	10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_T_cell\|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PPP1R10 ATP8A1 SYNE2 MACF1 UTRN	4.76e-05	193	91	5	a594f89a18273797506287d9e22f72abe53e4920
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	PTPRD SPTBN1 MACF1 DCN ADAM22	4.87e-05	194	91	5	b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PTPN3 PTPRD RHPN2 SYNE2 UGT2B7	4.87e-05	194	91	5	7002937e8903e037332a215d00fbc7c7843b33f2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	PTPN3 CLCN5 RHPN2 PLXNB1 CACNA2D3	4.87e-05	194	91	5	5eaaa81f4b2535f983c424aaef00077089526a5c
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	PTPRD SPTBN1 MACF1 DCN ADAM22	4.99e-05	195	91	5	0e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCell	3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ADRA2A SLC15A2 CFTR TMEM59 C3	4.99e-05	195	91	5	576142b4e75457c0973051bccc4163bd624496af
ToppCell	3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ADRA2A SLC15A2 CFTR TMEM59 C3	4.99e-05	195	91	5	8f151066ad3ebd9661ea0b733f03c2ce1518f9ad
ToppCell	facs-Thymus-Thymus_Epithelium\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD LPL KCNK2 C3 DCN	5.12e-05	196	91	5	6bc1187dfc4860a4e09032d7ea87ba3d9fe9f363
ToppCell	facs-Thymus-Thymus_Epithelium-18m\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRD LPL KCNK2 C3 DCN	5.12e-05	196	91	5	c8c89e469402e11aa2a9561e859b6fd1fb66c39b
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	PTPN3 CLCN5 RHPN2 UGT2B7 CACNA2D3	5.12e-05	196	91	5	6ce74aa3f0ce3ca284b67e5a4660ffd2cc9611e0
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	PTPRD LPL SPTBN1 MACF1 DCN	5.24e-05	197	91	5	31a1852911bda38543916585fda34255fd62a134
ToppCell	severe-unassigned\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CLCN4 ABCA13 RALGAPA2 NT5DC3 ADAM22	5.24e-05	197	91	5	70704b149b2820b8601d2495b7cd9cbe91eda262
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ATP8A1 SYNE2 C3 UTRN PLXNB1	5.24e-05	197	91	5	3d13a4f2e86422900ee2194e8a1fd1cf9750d5d3
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS_only / Treatment groups by lineage, cell group, cell type	ATP8A1 SLC15A2 SLC5A6 SYNE2 C3	5.24e-05	197	91	5	6b6504c47c309bac4f790e2f372d454bbdea49e8
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	PTPRD LPL SPTBN1 MACF1 DCN	5.24e-05	197	91	5	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	PTPRD LPL SPTBN1 MACF1 DCN	5.24e-05	197	91	5	11a4c417f035e554431a8f03be13b5eefa3530c0
ToppCell	356C-Lymphocytic-NK_cells-NK_cell_B1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	DPY19L2 CLCN5 HBZ PLXNB1	5.29e-05	100	91	4	cb0deaf1c33d2789417e93cc01d94e34a611d20a
ToppCell	LPS_only-Epithelial_alveolar-AT_2\|LPS_only / Treatment groups by lineage, cell group, cell type	ATP8A1 CFTR SEC11C C3 PLXNB1	5.37e-05	198	91	5	d087e738d69ca9853553fde46d4e7a8906439d32
ToppCell	LPS_only-Epithelial_alveolar\|LPS_only / Treatment groups by lineage, cell group, cell type	ATP8A1 SYNE2 SEC11C C3 PLXNB1	5.37e-05	198	91	5	655df75b9692d815c7f6910275e1f684ac63bf62
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RALGAPA1 SYNE2 RTTN MACF1 UTRN	5.50e-05	199	91	5	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	SLC15A2 SYNE2 UTRN PLXNB1 CACNA2D3	5.50e-05	199	91	5	d43c605a4ff221cf78d91678c15d2ad20f831c7f
ToppCell	ASK452-Epithelial-Type_1\|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq	SLC15A2 WFS1 SPTBN1 SYNE2 UTRN	5.50e-05	199	91	5	48cafe44951908d03f3c6f3e185e9cbb86fb5b3b
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	HTR1E ATP8A1 C3 ATP2A1 UTRN	5.50e-05	199	91	5	121de4e02585de3a3010398387c523bacf8ce546
ToppCell	wk_15-18-Mesenchymal-Fibroblast-Alveolar_fibro\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	PTPRD LPL SPTBN1 MACF1 DCN	5.50e-05	199	91	5	6bce8e65859a35cfea1c210f9c9765952d492ed2
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DPY19L2 MACF1 TRPV6 ADAM22 PLXNB1	5.50e-05	199	91	5	3cd6383c50ce342fe5c175e2e50784d634a90e80
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	PPP1R10 ATP8A1 CFTR C3 PLXNB1	5.63e-05	200	91	5	e8db082aa4d0597500e4f16a5c0ea3e62c6c59ae
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	PTPRD LPL SPTBN1 MACF1 DCN	5.63e-05	200	91	5	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	SPTBN1 SYNE2 MACF1 RALGAPA2 UTRN	5.63e-05	200	91	5	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Vein\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	RALGAPA1 ADAMTS6 CORO2A SYNE2 RALGAPA2	5.63e-05	200	91	5	7eb366b2c5394af7c77650bde6261e7dac67154e
ToppCell	control\|World / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	PTPN3 ABCA13 SPTBN1 SYNE2 PLXNB1	5.63e-05	200	91	5	97f36d2c197e03d93a1fc59949d77ae90f6e6a9a
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	DCHS2 SLC15A2 WFS1 MACF1 PLXNB1	5.63e-05	200	91	5	07d942803360e1a1e8e131d6e31c726dd0db1a0b
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte-Astrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	DCHS2 SLC15A2 WFS1 MACF1 PLXNB1	5.63e-05	200	91	5	d0812817ef99608994193787a62d39adeb2070ca
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Astrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	DCHS2 SLC15A2 WFS1 MACF1 PLXNB1	5.63e-05	200	91	5	cd54ddf1919c98e84b7e4aba85b374fc8b407206
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1-Calb1\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	WFS1 LPL TSKS SPAG5	1.08e-04	120	91	4	a6d0406a174d46ce06b41280292931954af88a59
ToppCell	Hippocampus-Macroglia-CSF_related-CHOROID_PLEXUS\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ABCA13 MC3R MBNL3 TMPRSS11A	1.34e-04	127	91	4	25d0b28c9df2d10fbcdb0aca47b75bf5c7c9c430
ToppCell	Hippocampus-Macroglia-CSF_related-CHOROID_PLEXUS-Choroid_Plexus.Ttr_(Ttr)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ABCA13 MC3R MBNL3 TMPRSS11A	1.34e-04	127	91	4	352d44233a93c926aeb7c5fad49965fd82b873ca
ToppCell	Hippocampus-Macroglia-CSF_related-CHOROID_PLEXUS-Choroid_Plexus.Ttr_(Ttr)--\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ABCA13 MC3R MBNL3 TMPRSS11A	1.34e-04	127	91	4	ca77f85502dd66f3cb4b15cf80f755104ca1e6ff
ToppCell	LPS_only-Epithelial_alveolar-AT_2-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ATP8A1 SYNE2 C3 CACNA2D3	1.34e-04	127	91	4	5b0adbcafad31a6759c9bdce2f7f9591a8edc450
ToppCell	Hippocampus-Macroglia-CSF_related-CHOROID_PLEXUS-Choroid_Plexus.Ttr_(Ttr)-\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ABCA13 MC3R MBNL3 TMPRSS11A	1.34e-04	127	91	4	b27d5141e661a4c6924aa6d7c5b046f9ae49955d
ToppCell	severe-unassigned\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CLCN4 ABCA13 NT5DC3 ADAM22	1.38e-04	128	91	4	bef9cf0078fa8498d63f0723f1fa4a3c92405e10
ToppCell	NS-moderate-d_07-13-Epithelial-unknown_epithelial\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	PPP1R10 PTPRD ABCA13 PLXNB1	1.46e-04	130	91	4	1491e8975520e99c527a5b5bee64875d124f7bf4
ToppCell	Hippocampus-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Cbln1-Excitatory_Neuron.Slc17a7.Cbln1-Trps1_(Medial_entorrhinal_cortex,_Cbln1+/Trps1+)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	WFS1 MC3R CDH23	1.55e-04	51	91	3	10cfed29c2fa495d4527e1e4d8edf21edaf1d0fa
Drug	atropine sulfate	ADRA2A CLCN4 CLCN5 HTR7 CFTR DCN ATP2A1 MED12 DSE	7.22e-06	347	87	9	CID000003661
Drug	niflumic acid	CLCN4 CLCN5 PIK3CG CFTR UGT2B7 DCN	8.52e-06	125	87	6	CID000004488
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; PC3; HT_HG-U133A	CLCN4 CATSPER2 CORO2A SPTBN1 C3 DCN ADAM22	8.69e-06	191	87	7	3803_DN
Drug	Cl- co	LIG4 CFTR C3	8.70e-06	11	87	3	CID000137656
Drug	Carbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A	RALGAPA1 ATP8A1 SPTBN1 TSKS DCN ADAM22 PLXNB1	1.03e-05	196	87	7	3380_UP
Drug	plakin	SPTBN1 SYNE2 MACF1 UTRN TXNDC11	1.57e-05	82	87	5	CID000018752
Drug	AC1OAGFB	PTPN3 CLCN5 MTOR PIK3CG PI4KA LPL SPTBN1 CDH23 TRPV6 TXNDC11	3.97e-05	539	87	10	CID006857345
Drug	Medetomidine	ADRA2A CFTR	4.32e-05	3	87	2	ctd:D020926
Drug	myo-inositol	LIG4 PTPN3 ADRA2A FCGR1A HTR7 MTOR PIK3CG PI4KA LPL TRPV6 ATP2A1 CACNA2D3	5.88e-05	811	87	12	CID000000892
Drug	AC1Q3ZOL	NPFFR2 CLCN4 CLCN5 HTR7 CFTR DCN MED12	5.97e-05	258	87	7	CID000002376
Drug	carbachol	NPFFR2 PTPN3 ADRA2A PIK3CG PI4KA LPL CFTR TRPV6 DCN ATP2A1 CACNA2D3	6.16e-05	688	87	11	CID000002551
Drug	RHC 80267	PTPN3 HTR7 LPL DCN DSE	7.06e-05	112	87	5	CID000005063
Drug	selezen	HTR7 DCN	8.62e-05	4	87	2	CID000037425
Drug	8-OH-DPAT	ADRA2A HTR1E HTR7 MTOR CFTR	8.68e-05	117	87	5	CID000001220
Drug	Flumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A	ATP8A1 CLCN4 TEX15 DCN ADAM22 SYMPK	9.80e-05	193	87	6	3712_DN
Drug	Nifuroxazide [965-52-6]; Down 200; 14.6uM; PC3; HT_HG-U133A	LIG4 CORO2A TEX15 UTRN ADAM22 PLXNB1	9.80e-05	193	87	6	4253_DN
Drug	pindolol	ADRA2A HTR1E HTR7 LPL	9.97e-05	63	87	4	CID000004828
Drug	Methapyrilene hydrochloride [135-23-9]; Up 200; 13.4uM; PC3; HT_HG-U133A	DCHS2 CLCN4 LPL MC3R DCN ADAM22	1.01e-04	194	87	6	6644_UP
Drug	Methoxy-8-psoralen [298-81-7]; Up 200; 18.6uM; MCF7; HT_HG-U133A	CLCN4 SPTBN1 CFTR UTRN ADAM22 SYMPK	1.04e-04	195	87	6	5007_UP
Drug	dimyristoylphosphatidylcholine	MTOR LPL SPTBN1 HBZ	1.06e-04	64	87	4	CID000026197
Drug	Novobiocin sodium salt [1476-53-5]; Down 200; 6.4uM; MCF7; HT_HG-U133A	HTR1E CFTR TRPV6 METTL16 NT5DC3 ADAM22	1.07e-04	196	87	6	4392_DN
Drug	PF-00539758-00 [351321-34-1]; Up 200; 10uM; MCF7; HT_HG-U133A	RIF1 SPTBN1 MC3R C3 SERPINA10 ADAM22	1.07e-04	196	87	6	6416_UP
Drug	Piperacillin sodium salt [59703-84-3]; Up 200; 7.4uM; PC3; HT_HG-U133A	HTR1E CLCN4 KCNK2 CUL9 C3 ADAM22	1.07e-04	196	87	6	3763_UP
Drug	Piretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A	HTR1E CORO2A DNAJC16 SPTBN1 DSE PLXNB1	1.07e-04	196	87	6	3567_DN
Drug	nordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A	CLCN4 KCNK2 METTL16 ATP2A1 UTRN ADAM22	1.07e-04	196	87	6	5583_UP
Drug	glibenclamide	RALGAPA1 CLCN4 CLCN5 ABCA13 CFTR KCNK2 DCN HBZ	1.07e-04	382	87	8	CID000003488
Drug	Clobetasol propionate [25122-46-7]; Down 200; 8.6uM; MCF7; HT_HG-U133A	LIG4 CLCN5 TRPV6 ADAM22 DSE PLXNB1	1.10e-04	197	87	6	6095_DN
Drug	Sertaconazole nitrate [99592-39-9]; Down 200; 8uM; MCF7; HT_HG-U133A	HTR1E CLCN5 SLC15A2 NT5DC3 ADAM22 MBNL3	1.10e-04	197	87	6	3550_DN
Drug	Bambuterol hydrochloride [81732-46-9]; Up 200; 10uM; MCF7; HT_HG-U133A	LIG4 HTR1E CUL9 TEX15 DCN ADAM22	1.10e-04	197	87	6	7239_UP
Drug	Oxaprozin [21256-18-8]; Down 200; 13.6uM; PC3; HT_HG-U133A	RALGAPA1 CATSPER2 C3 DCN NT5DC3 UTRN	1.10e-04	197	87	6	4530_DN
Drug	Quinethazone [73-49-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A	HTR1E CLCN4 APC2 CUL9 C3 CD160	1.13e-04	198	87	6	4351_UP
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Up 200; 9uM; MCF7; HT_HG-U133A	ATP8A1 SPTBN1 TSKS DCN ADAM22 PLXNB1	1.13e-04	198	87	6	5263_UP
Drug	Cefaclor [70356-03-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A	HTR1E SPTBN1 EFCAB14 METTL16 UTRN MED12	1.13e-04	198	87	6	4967_DN
Drug	Indapamide [26807-65-8]; Up 200; 10.6uM; PC3; HT_HG-U133A	RIF1 ATP8A1 HTR7 ADAMTS6 SERPINA10 PLXNB1	1.13e-04	198	87	6	3778_UP
Drug	Nafcillin sodium salt monohydrate [7177-50-6]; Up 200; 8.8uM; HL60; HT_HG-U133A	RALGAPA1 RIF1 HTR1E CLCN4 DCN DOP1A	1.13e-04	198	87	6	2983_UP
Drug	Glimepiride [93479-97-1]; Up 200; 8.2uM; MCF7; HT_HG-U133A	CLCN4 CLCN5 PLXNB1 MBNL3 DOP1A SYMPK	1.16e-04	199	87	6	4973_UP
Drug	Bacampicillin hydrochloride [37661-08-8]; Up 200; 8uM; PC3; HT_HG-U133A	RIF1 CLCN4 LPL CFTR TSKS DCN	1.16e-04	199	87	6	4592_UP
Drug	Epirizole [18694-40-1]; Up 200; 17uM; MCF7; HT_HG-U133A	CATSPER2 DNAJC16 C3 TEX15 NT5DC3 ADAM22	1.16e-04	199	87	6	5995_UP
Drug	Olanzapine	ADRA2A HTR1E HTR7	1.17e-04	25	87	3	DB00334
Drug	Ziprasidone	ADRA2A HTR1E HTR7	1.17e-04	25	87	3	DB00246
Drug	Aripiprazole	ADRA2A HTR1E HTR7	1.17e-04	25	87	3	DB01238
Drug	Promazine hydrochloride [53-60-1]; Up 200; 12.4uM; PC3; HT_HG-U133A	RALGAPA1 ADAMTS6 DNAJC16 APC2 C3 ADAM22	1.19e-04	200	87	6	3752_UP
Drug	Clozapine	ADRA2A HTR1E HTR7	1.31e-04	26	87	3	DB00363
Drug	Quetiapine	ADRA2A HTR1E HTR7	1.31e-04	26	87	3	DB01224
Drug	olanzapine	ADRA2A HTR1E HTR7 LPL C3	1.38e-04	129	87	5	CID000004585
Drug	chloride	ADRA2A HTR1E CLCN4 CLCN5 HTR7 SLC15A2 SLC5A6 CFTR TRPV6 METTL16 ATP2A1 AQP7 TXNDC11	1.39e-04	1029	87	13	CID000000312
Drug	mitiglinide	LPL CFTR UGT2B7	1.48e-04	27	87	3	CID000121891
Drug	ketanserin	ADRA2A HTR1E HTR7 MTOR DCN	1.48e-04	131	87	5	CID000003822
Drug	1-phenylpyrazole	CLCN4 CLCN5 CFTR	1.65e-04	28	87	3	CID000070769
Disease	obesity (implicated_via_orthology)	DCHS2 SLC15A2 LPL MC3R C3 MED12 PLXNB1 PLXNB3	2.49e-07	215	87	8	DOID:9970 (implicated_via_orthology)
Disease	Dent disease (implicated_via_orthology)	CLCN4 CLCN5	2.57e-05	3	87	2	DOID:0050699 (implicated_via_orthology)
Disease	susceptibility to rheumatic fever measurement	XYLT1 PTPRD CACNA2D3	7.69e-05	28	87	3	EFO_0008416
Disease	osteopetrosis (implicated_via_orthology)	CLCN4 CLCN5	1.79e-04	7	87	2	DOID:13533 (implicated_via_orthology)
Disease	platelet aggregation	ADRA2A PTPRD CACNA2D3	3.21e-04	45	87	3	GO_0070527
Disease	insomnia measurement	PPP1R10 ADRA2A PTPRD SEC11C TEX15 METTL16 CACNA2D3	3.41e-04	443	87	7	EFO_0007876
Disease	Intellectual Disability	RALGAPA1 MTOR SLC5A6 APC2 RTTN MACF1 PREPL	3.60e-04	447	87	7	C3714756
Disease	Fibrosis	ADRA2A PIK3CG DCN	4.39e-04	50	87	3	C0016059
Disease	Cirrhosis	ADRA2A PIK3CG DCN	4.39e-04	50	87	3	C1623038
Disease	liver cirrhosis (implicated_via_orthology)	FOCAD PIK3CG	6.56e-04	13	87	2	DOID:5082 (implicated_via_orthology)
Disease	protein-glutamine gamma-glutamyltransferase e measurement	PTPN3 RHPN2 SLC5A6	7.50e-04	60	87	3	EFO_0020690
Disease	Mental Depression	ADRA2A HTR7 WFS1 KCNK2 MED12	9.45e-04	254	87	5	C0011570
Disease	type 2 diabetes mellitus (biomarker_via_orthology)	ADRA2A MTOR LPL ATP2A1	9.55e-04	147	87	4	DOID:9352 (biomarker_via_orthology)
Disease	Rolandic epilepsy	DPY19L2 PTCHD3	1.00e-03	16	87	2	Orphanet_1945
Disease	Colorectal Neoplasms	PTPRD RHPN2 ABCA13 CFTR APC2	1.39e-03	277	87	5	C0009404
Disease	type 2 diabetes mellitus (is_implicated_in)	ADRA2A WFS1 MTOR LPL	1.67e-03	171	87	4	DOID:9352 (is_implicated_in)
Disease	Depressive disorder	ADRA2A HTR7 WFS1 KCNK2 MED12	1.67e-03	289	87	5	C0011581
Disease	waist circumference	RALGAPA1 HTR1E CFTR SYNE2 TEX15 ATP2A1	1.71e-03	429	87	6	EFO_0004342
Disease	gestational age, birth measurement	PTPRD CACNA2D3	1.74e-03	21	87	2	EFO_0005112, EFO_0006921
Disease	Nephritis, Tubulointerstitial	CLCN5 DCN	1.74e-03	21	87	2	C0041349
Disease	anxiety disorder (implicated_via_orthology)	ADRA2A HTR7	1.91e-03	22	87	2	DOID:2030 (implicated_via_orthology)
Disease	level of Sphingomyelin (d40:2) in blood serum	NPFFR2 SYNE2	2.09e-03	23	87	2	OBA_2045181
Disease	Nephritis, Interstitial	CLCN5 DCN	2.27e-03	24	87	2	C0027707
Disease	atrophic macular degeneration	C3 TEX15	2.47e-03	25	87	2	EFO_1001492
Disease	glycerol measurement	AQP7 HERC2P3	2.67e-03	26	87	2	EFO_0010115
Disease	blood rubidium measurement	RIF1 ABCA13	2.67e-03	26	87	2	EFO_0021529
Disease	diabetes mellitus (implicated_via_orthology)	WFS1 CFTR	2.67e-03	26	87	2	DOID:9351 (implicated_via_orthology)
Disease	gout	PTPRD CFTR CD160 CACNA2D3	2.73e-03	196	87	4	EFO_0004274
Disease	age-related hearing impairment	XYLT1 HTR1E SPTBN1 CDH23 DPY19L2P2	2.74e-03	324	87	5	EFO_0005782

Protein segments in the cluster

Peptide	Gene	Start	Entry
VTWIKTIRSTMIINL	ERVK-18	516	O42043
IILTLAMNIMSTLQW	CFTR	1131	P13569
MVEIELLESTNTKLW	CATSPER2	126	Q96P56
KVWVMLVTSLVALQA	CD160	166	O95971
AKRAALMILTVWTIS	HTR1E	136	P28566
LKTRIVLVAMETWAT	ADAM22	281	Q9P0K1
MNIFLKDSITTWEIL	C3	791	P01024
ILQEVITWHKNMSVL	ABCA13	556	Q86UQ4
MNSILKIVTWVLNIK	ABCA13	1431	Q86UQ4
LTSLWPTMITELVQV	DOP1A	2236	Q5JWR5
LSITMEVILIIKYWT	ATP8B3	1126	O60423
KWTLLIKTVTLVLVV	CLCN4	201	P51793
LWGTTMLLVEVIDVN	CDH23	2591	Q9H251
WINITEMNKQISLLT	EFCAB14	151	O75071
ALDLTQWLMVLKISL	ATP2A1	961	O14983
IETLMKADIKIWILT	ATP8A1	671	Q9Y2Q0
KTLTWILSLIMASSE	ADAMTS6	6	Q9UKP5
SEKKDTMIIWQITIT	ATP1A1-AS1	76	Q5TC04
KLTIKTAFVIIMIIW	NPFFR2	256	Q9Y5X5
REWVLKSSILIAMAV	INTS3	196	Q68E01
VVWDQKLSLIVMLTT	PTPN3	731	P26045
INIMVLKVDTSESLW	KIAA0100	141	Q14667
ISFVGTWMKLETIIL	nan	1241	O00370
TWMKLETIILSKLSQ	nan	1246	O00370
VKMIQVWRDVSLDSV	LGALS16	121	A8MUM7
VMKWKTVSTIFLVVV	KCNK2	56	O95069
TVVEKLLTNWMSICL	PLXNB1	1681	O43157
TETMVEKLLTNWLSI	PLXNB3	1446	Q9ULL4
MESKALLVLTLAVWL	LPL	1	P06858
MKATIILLLLAQVSW	DCN	1	P07585
ITKMLWSTRTLLNIT	CES4A	376	Q5XG92
MEVRKLSISWQFLIV	DNAJC16	1	Q9Y2G8
LWSGTVLKTMLDILQ	PI4KA	1001	P42356
VVTTWIEKILTDLKV	METTL16	341	Q86W50
LWTKQVLTIMEKSLV	DSE	231	Q9UL01
TQQTTEWAMLLLEII	MED12	1551	Q93074
MVSWSVIAKIQEILQ	AQP7	16	O14520
LEEWQVSVLTLMTKQ	RFPL4B	61	Q6ZWI9
SLLMTWAIILKRNEI	DPY19L2	401	Q6NUT2
KTWEQMLQILLRITE	RALGAPA2	561	Q2PPJ7
TLIKWIEETTAQQEM	MACF1	1286	Q9UPN3
WLSLISIMEKDIVNL	DCHS2	3071	Q6V1P9
TERTIIVSMWAKIST	HBZ	6	P02008
SKVEVVFWLLSMLAT	APC2	271	O95996
TQSSALEQKWLIRMI	LIG4	176	P49917
AFLSAVKWIMTELVL	CACNA2D3	926	Q8IZS8
SAMWQLALTLILKIV	CLCN5	496	P51795
KVMIWNLDTKESVIT	CORO2A	156	Q92828
TLWMANTIKLLDLVE	MTFMT	276	Q96DP5
MTAVNVALIRDTKWL	MBNL3	1	Q9NUK0
MTVRKALTLIVAIWV	MC3R	156	P41968
IMFLVNTVLWVTIRK	FCGR1A	301	P12314
KQILHVSTVQMWLLL	CUL9	1766	Q8IWT3
IMGTLSSWNLKILQI	CA5BP1	11	Q8WTZ4
MKSVLQAAWLLTIAV	SLC15A2	641	Q16348
SLLMTWAIILKRNEI	DPY19L2P2	211	Q6ZN68
KEWVSMVLDTLLVIV	FOCAD	996	Q5VW36
WKVNLDSISMINLVI	PTCHD3	846	Q3KNS1
ARMLSSTTILVQWKE	PTPRD	426	P23468
EDWQKILMVRSLVVS	MTOR	1631	P42345
TLIWNTCELLKDVIM	RTTN	201	Q86VV8
WLVLIDQMLKSNIVT	UTRN	2241	P46939
LLSLTQMEREKIVWE	TRIM27	171	P14373
RNVMQSWVLISKELI	SPAG5	501	Q96R06
VSSALMIWKGLIVLT	SEC11C	41	Q9BY50
SILVWLTEMDLQLTN	SYNE2	6256	Q8WXH0
VVVSAIWKELISLVK	RIF1	496	Q5UIP0
LKAVIWTDVFQTLVM	SLC5A6	196	Q9Y289
IQTMTWLQTLTGLLE	NT5DC3	426	Q86UY8
AIIMTDLFTKWIVIL	GIN1	161	Q9NXP7
LMTLVTLLILVWKVT	SMIM42	36	A0A5F9ZH02
LSSLQWITLLMKVVE	HERC2P3	756	Q9BVR0
STVLWETMLLQLLKE	MROH2B	566	Q7Z745
IQLVDCKWLTLSEVM	RHPN2	561	Q8IUC4
IDAWMLDILKIVSSS	SPTBN1	756	Q01082
KMILSVWLLSASITL	HTR7	201	P34969
KAIIITVWVISAVIS	ADRA2A	166	P08913
QILRIMESIWETESL	PIK3CG	846	P48736
LLWVLTDSQLKAMVQ	UHRF1BP1L	241	A0JNW5
ILTTTLVLSVMVLLW	TMEM59	241	Q9BXS4
NLAVSKLETLETWVM	XYLT1	706	Q86Y38
EWSLTMETLTKVLAR	RALGAPA1	661	Q6GYQ0
NSLIADMEKVLVVWI	TIGD1	76	Q96MW7
ELWRAQIVATTVMLE	TRPV6	631	Q9H1D0
TINIMNKTTSEVWLI	PREPL	266	Q4J6C6
MASVVVKTIWQSKEI	TSKS	1	Q9UJT2
LQWMVKSRVISELQE	SYMPK	141	Q92797
LTTDLVETWLRNMKT	SERPINA10	316	Q9UK55
TENTWLKILVATMER	TXNDC11	916	Q6PKC3
METLLGVSLVILWLQ	TRAV17	1	A0A0B4J275
WIIIEMISSKVNFIK	TEX15	1856	Q9BXT5
MSVKWTSVILLIQLS	UGT2B7	1	P16662
MVLKFSVSILWIQLA	TRAV27	1	A0A087WT01
KLASVLVSDWMAVIR	PPP1R10	131	Q96QC0
WSLMLKEVLSSILKV	VIRMA	1091	Q69YN4
KPWMIAVLIVLSLTV	TMPRSS11A	16	Q6ZMR5
METLLKVLSGTLLWQ	TRAV30	1	A0A087WSZ9
SLTRSSMVKLILVWL	WFS1	626	O76024
SMVKLILVWLTAIVL	WFS1	631	O76024